

IMPACT FACTSHEET

Novo Nordisk

Main impact area

WHAT	 <i>Is the outcome important?</i>	Reduce premature mortality (SDG 3.4)
WHO	 <i>Does this help people in need?</i>	450 million people need insulin daily
HOW MUCH	 <i>Scale</i> <i>Depth</i> <i>Duration</i>	Novo reaches 32+ mln people in 170 countries Providing insulin at controlled price Long term
CONTRIBUTION	 <i>How do the alternatives do?</i>	Uninsured clients / 25% revenues from EM
RISK	 <i>What if it doesn't go as planned?</i>	Low probability

WHAT

- Diabetes is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. It is Novo Nordisk's purpose to defeat diabetes and other serious diseases through running state of the art research and development, accelerating prevention and providing access to affordable care for vulnerable patients.
- The Kempen Sustainable Equity Strategy seeks to proactively contribute to Good health & Well-being.

WHO

- There are an estimated 450 million people diagnosed with diabetes who depend on insulin on a daily basis to maintain a normal lifestyle.
- High blood sugar causes various medical complications leading to an average 12 years less life-expectancy for people with type 1 diabetes*.

HOW MUCH

- Overall, 32 million patients are provided with medicine for diabetes on an annual basis in around 170 countries.
- Novo Nordisk has a Preferential Pricing Policy for Access to Insulin Commitment by providing insulin at the guaranteed ceiling price (3 USD per vial) in the low-income countries. Based on this policy 6.4 million people in 76 countries received access to the low-priced human insulin.
- Around 25% (31,5 DKK bn) of sales in 2020 were generated in emerging economies. Diabetes has risen sharply in emerging economies in the past two decades due to rapid industrialization, more sedentary lifestyles and less healthy diet.
- Novo Nordisk invests 10.8% (DKK 13.7 bn) of net sales in R&D.

COMPANY CONTRIBUTION

- If patients take medications correctly and take a good care of their lifestyle their life expectancy can reach same level as people without diagnosis. Under this assumption, products of Novo Nordisk in the diabetes market save 384 million years of total life expectancy for its patients.
- Pro-rated as per our investment in Novo Nordisk, we have contributed to saving approximately 7,450 years of total life. Our investment, pro-rated provided access to 595 people to the low-priced human insulin.
- The company also provides medicines for hemophilia, growth disorders and hormone replacement. Novo Nordisk is also developing treatment for NASH (Non-alcoholic steatohepatitis), a disease with no available treatment.

OUR CONTRIBUTION

- Engagement with Novo Nordisk – see Engagement Factsheet

RISK

- It is unlikely that Novo Nordisk will not live up to its commitment to help eradicate premature death from diabetes.



SDG 3 Good Health and Well-being: sub target 3.4 – reduction of premature mortality from non-communicable diseases (NCDs) through prevention and treatment by a third by 2030.

TYPE 2 DIABETES FACTS

90%

of all diabetes cases are type 2 diabetes globally.

380m

people live with type 2 diabetes globally.

2-4x

the increased risk of cardiovascular disease.

7x

the increased risk of developing type 2 diabetes for someone living with obesity.